The response of Continuous Erythropoietic Receptor Activator (CERA) with different dose interval and the survey for influence factors: We aim to evaluate a better clinical response which can be achieved by different dosing interval of a fixed dose of CERA. We expect this study can determine the dosing schedule with better clinical response to CERA and identify the associated factors predicting the cost-effectiveness of CERA in maintenance hemodialysis (HD) patients in Taiwan.
We included HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we measured and compared the erythropoietic response (hematocrit, hemoglobin), profiles of iron status as well as nutritional status and inflammatory markers among the study subjects every two months for a total of 6 months. Those who had bleeding or received surgery or blood transfusion were excluded.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
67
changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan
Erythropoietic response
We measured and compared the hematocrit, hemoglobin, and iron status profiles (ferritin, iron, total iron binding capacity) among those enrolled patients every 2 months for 6 months totally.
Time frame: every 2 months for six months
Nutritional status and inflammatory markers
Nutritional status (albumin, prealbumin) and inflammatory markers \[interleukin 6, tumor necrosis factor-α (TNF-α)\]
Time frame: every 2 months for a total of 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.